Literature DB >> 2683022

Campylobacter pylori--therapy review.

A T Axon1.   

Abstract

Although Campylobacter pylori is sensitive to many antibiotics in vitro, few are effective in vivo. Furthermore, treatment regimens which successfully clear the organism in vivo are associated with high recurrence rates when assessed one month following treatment. On the other hand, 85% of those individuals who are C. pylori negative 1 month after the cessation of therapy remain negative at 12 months and the infection can be considered to be eradicated. Treatment with certain bismuth salts appears to be the most useful monotherapy, eradicating the organism in approximately 19% whilst dual therapy with bismuth plus ampicillin or tinidazole is more effective, eradicating infection in 32% and 78% respectively. Preliminary data suggest that triple therapy with bismuth, amoxicillin and metronidazole, or bismuth, tetracycline and metronidazole eradicates the infection in over 90%.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2683022     DOI: 10.3109/00365528909091733

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  11 in total

1.  In vitro susceptibility of Helicobacter pylori to the new oral cephalosporins cefpodoxime, ceftibuten and cefixime.

Authors:  T U Westblom; S Gudipati; B R Midkiff
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-09       Impact factor: 3.267

2.  Susceptibility of Helicobacter pylori to metronidazole.

Authors:  M López-Brea; E Martín; C López-Lavid; J C Sanz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-12       Impact factor: 3.267

3.  Synergistic effects between amoxicillin, metronidazole, and the hydroxymetabolite of metronidazole against Actinobacillus actinomycetemcomitans.

Authors:  M J Pavicić; A J van Winkelhoff; J de Graaff
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

4.  Azithromycin levels in plasma and gastric tissue, juice and mucus.

Authors:  J D Harrison; J A Jones; D L Morris
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

5.  One-day high-dose combined therapy of Helicobacter pylori infection.

Authors:  A Dobrucali; M Tuncer; Y T Eralp; S Goksel; M Altin; I Dinc
Journal:  Dig Dis Sci       Date:  1997-10       Impact factor: 3.199

6.  Detection of Helicobacter pylori in dental plaque by reverse transcription-polymerase chain reaction.

Authors:  A M Nguyen; L Engstrand; R M Genta; D Y Graham; F A el-Zaatari
Journal:  J Clin Microbiol       Date:  1993-04       Impact factor: 5.948

7.  One-day therapy for treatment of Helicobacter pylori infection.

Authors:  A Tucci; R Corinaldesi; V Stanghellini; G F Paparo; S Gasperoni; G Biasco; O Varoli; M Ricci-Maccarini; L Barbara
Journal:  Dig Dis Sci       Date:  1993-09       Impact factor: 3.199

8.  Enhancement of antibiotic concentrations in gastric mucosa by H2-receptor antagonist. Implications for treatment of Helicobacter pylori infections.

Authors:  T U Westblom; D E Duriex
Journal:  Dig Dis Sci       Date:  1991-01       Impact factor: 3.199

9.  Difficulty in eradicating Helicobacter pylori in a population at high risk for stomach cancer in Venezuela.

Authors:  E Buiatti; N Muñoz; J Vivas; E Cano; S Peraza; E Carillo; D Castro; V Sanchez; O Andrade; M Benz
Journal:  Cancer Causes Control       Date:  1994-05       Impact factor: 2.506

10.  Combined activity of trospectomycin and colloidal bismuth subcitrate against Helicobacter pylori in vitro.

Authors:  K Vogt; A C Rodloff; H Hahn
Journal:  Infection       Date:  1991 May-Jun       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.